Abstract

BackgroundBrain metastases (BMs) are associated with poor prognosis and significant mortality, and approximately 25% of patients with non–small cell lung cancer (NSCLC) develop BMs. The present study was aimed to understand the relationships between BM and NSCLC and reveal potential biomarkers and therapeutic targets in NSCLC-related BM.MethodsThe differentially expressed genes (DEGs) expressed during NSCLC and BM development were predicted by bioinformatics analysis, and the expression of the upstream transcription factor nuclear factor of activated T cells (NFAT) was confirmed as a differential gene expressed in both NSCLC and BM. In addition, the expression of proteins encoded by these DEGs was verified by immunohistochemical experiments examining normal lung tissue, lung cancer tissue, and brain metastasis tissue from 30 patients with NSCLC related BM.ResultsThe co-DEGs interleukin (IL)-11, cadherin 5 (CDH5) and C-C motif chemokine 2 (CCL2) link NSCLC and BM in the Gene Expression Omnibus (GEO) database, and NFAT may target the expression of these co-DEGs. In the GEO database, NFATc1 and NFATc3 were significantly downregulated in NSCLC tissues (P <.05), whereas NFATc1, NFATc2, NFATc3, and NFATc4 were significantly downregulated in BMs (P <.05). Consistent findings were observed in the immunohistochemical analysis.ConclusionNFATc1 and NFATc3 may play important roles in the occurrence of NSCLC and BM by regulating IL-11, CDH5, and CCL2.

Highlights

  • Brain metastases (BMs) are associated with poor prognosis and significant mortality, and they are the most common central nervous system malignancies, developing in 20–40% of advanced-stage cancers; 40–50% of these cases occur in patients with lung cancer [1]

  • BM-differentially expressed gene (DEG) and non-small cell lung cancer (NSCLC)-DEGs were confirmed in GSE161116, GSE74706, and GSE21933

  • In GSE161116, there were 282 DEGs between brain and lung tumor specimens from BM patients, which we defined as BM-related DEGs (BM-DEGs)

Read more

Summary

Introduction

Brain metastases (BMs) are associated with poor prognosis and significant mortality, and they are the most common central nervous system malignancies, developing in 20–40% of advanced-stage cancers; 40–50% of these cases occur in patients with lung cancer [1]. Approximately 25% of patients with non-small cell lung cancer (NSCLC) develop BMs [2], and NSCLC accounts for about 88% of NFAT as a Biomarker primary lung malignancies [3, 4]. Brain metastases (BMs) are associated with poor prognosis and significant mortality, and approximately 25% of patients with non–small cell lung cancer (NSCLC) develop BMs. The present study was aimed to understand the relationships between BM and NSCLC and reveal potential biomarkers and therapeutic targets in NSCLC-related BM

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.